The efficacy of selenium, WR-2721, and their combination in the prevention of adriamycin-induced cardiotoxicity in rats

Journal of Environmental Pathology, Toxicology and Oncology

Volumn 17, Issue 3-4, 1998, Pages 291-299

  Dobrić, Silva ^a   Dragojević Simić, Viktorija ^a   Bokonjić, Dubravko ^a   Milovanović, Slobodan ^a   Marinčić, Dragan ^a   Jović, Pavle ^a  

^a UNIVERSITY OF DEFENCE   (Serbia)

Author keywords

Adriamycin; Amifostine; Cardioprotection; Cardiotoxicity; Myocardial injury; Selenium; WR 2721

Indexed keywords

AMIFOSTINE; DOXORUBICIN; SELENIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOTOXICITY; DRUG EFFECT; ELECTROCARDIOGRAM; ENZYME ACTIVITY; ENZYME ASSAY; HEART PROTECTION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TISSUE DISTRIBUTION;

ACONITINE; AMIFOSTINE; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ARRHYTHMIA; ASPARTATE AMINOTRANSFERASES; CREATINE KINASE; DOXORUBICIN; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; HEART DISEASES; HYDROXYBUTYRATE DEHYDROGENASE; L-LACTATE DEHYDROGENASE; MALE; RADIATION-PROTECTIVE AGENTS; RATS; RATS, WISTAR; SELENIUM;

ANIMALIA; RATTUS NORVEGICUS;

EID: 0031874231     PISSN: 07318898     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Chabner BA, Allegra CJ, Curt GA, Calabresi P. Antineoplastic agents. In: Hardman JG, Limbird LE, eds. Goodman and Gilman.s the pharmacological basis of therapeutics, 9th ed. New York-Toronto: McGraw-Hill, 1996: 1233-1287.
2. Bachur NR, Gordon SL, Gee MV. A general mechanism for microsomal activation of quinone anticancer agents to free radicals. Cancer Res 1978; 38:1745-1750.
3. Goodman J, Hochstein P. Generation of free radicals and lipid peroxidation by redox cycling of adryamicin and daunomycin. Biochem Biophys Res Commun 1977; 77:797-803.
4. Doroshow JH. Anthracycline antibiotic-stimulated superoxide, hydrogen peroxide and hydroxyl radical production by NADH dehydrogenase. Cancer Res 1983; 43:4543-4551.
5. Griffen-Green EA, Erecinska M. Adryamicin induced lipid peroxidation in mitochondria and microsomes. Biochem Pharmacol 1988; 37: 3071-3077.
6. Doroshow JH, Locker GY, Myers CE. Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin. J Clin Invest 1980; 65:128-135.
7. Van Vleet JF, Greenwood L, Ferrons VJ, Reban AH. Effect of selenium-vitamin E on adryamicin-induced cardiomyopathy in rabbits. Am J Vet Res 1978; 39:997-1010.
8. Dimitrov NV, Zhang ZF, Sun J, Si L, Xu GL, Wang SC, Texera C, Siew S. Amelioration of doxorubicin-induced cardiotoxicity by selenium in animals and humans. Proc Am Soc Clin Oncol 1985; 4:27.
9. Dimitrov NV, Hay MB, Siew S, Hudler DA, Charamella LJ, Ullrey DE. Abrogation of adryamicin-induced cardiotoxicity by selenium in rabbits. Am J Pathol 1987; 126:376-383.
10. Jotti A, Maiorino M, Paracchini L, Piccinini F, Ursini F. Protective effect of dietary selenium supplementation on delayed cardiotoxicity of adriamycin in rat: is PHGPX but not GPX involved? Free Rad Biol Med 1994; 16:283-288.
11. Greisser-Aleksić N, Nikolić V, Bogdanović G, Baltić V, Spasić M. Preventing doxorubicin cardiotoxicity by selenium. Onkol Arh 1994; 2:195-197 (in Serbian with English abstract).
12. Sweeney TR. A survey of compounds from the antiradiation drug development program of the US Army Medical Research and Development Command. Washington DC, Walter Reed Army Inst Res, 1979.
13. Mahaney FX Jr. Agent designed for war now in doctors' armamentarium. J Natl Cancer Inst 1990; 82:255-257.
14. Giambarresi L, Jacobs AJ. Radioprotectants. In: Conklin JJ, Walker RI, eds. Military radiobiology. New York: Academic Press, 1987: 265-301.
15. Spencer CM, Goa KL. Amifostine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential as a radioprotector and cytotoxic chemoprotector. Drugs 1995; 50:1001-1031.
16. Schein PS. WR-2721: a chemotherapy and radiation-protective agents. Cancer Invest 1990; 8:265-266.
17. Wasserman TH. Radiotherapeutic studies with amifostine (Ethyol). Semin Oncol 1994; 21(Suppl 11):21-25.
18. Capizzi RL. Protection of normal tissues from the cytotoxic effects of chemotherapy by amifostine (Ethyol): clinical experiences. Semin Oncol 1994; 21 (Suppl 11):8-15.
19. Raschack M. Wirkung von Ajmalin und seinen therapeutisch verwendeten Derivaten N-Propylajmalin und Di-monochloracetylajmalin auf funktionelle Refraktarzeit und Kontraktionskraft am Meerschweinchenvorhof sowie Aconitin-Arrhythmien an der Ratte. Arzneim Forsch 1975; 25:639-641.
20. Anders RJ, Shanes JG, Zeller FP. Lower incidence of doxorubicin-induced cardiomyopathy by once-a-week low dose administration. Am Heart J 1991; 111:755-759.
21. Jensen RA, Acton EM, Peters JH. Doxorubicin cardiotoxicity in the rat: comparison of electrocardiogram, transmembrane potential, and structural effects. J Cardiovasc Pharmacol 1984; 6:186-200.
22. Rossi F, Filippelli W, Russo S, Filippelli A, Berrino L. Cardiotoxicity of doxorubicin: effects of drugs inhibiting the release of vasoactive substances. Pharmacol Toxicol 1994; 75:99-107.
23. Bokonjić D, Dobrić S, Prokić V, Bošković B. The role of benzodiazepines in prevention of delayed neural and cardiac toxicity of soman and VX in rats. Arch Toxicol Kinet Xenobiot Metab 1994; 2:445-446.
24. Dobrić S, Bokonjić D, Vučinic Ž, Popović M. Cardioprotective effects of propranolol and verapamil in soman poisoned rats. Arch Toxicol Kinet Xenobiot Metab 1994; 2:447-448.
25. Dobrić S, Bokonjić D, Popović M. Cardiotoxicity of aconitine in irradiated rats. Arh Farm 1995; 45:346-347 (in Serbian with English abstract).
26. Olson HM, Capen CC. Subacute cardiotoxicity of adriamycin in the rat. Biochemical and ultrastructural investigations. Lab Invest 1977; 37: 386-394.
27. Van Vleet JF, Greenwood L, Ferrons VJ, Reban AH. Effect of selenium-vitamin E on adriamycin-induced cardiomyopathy in rabbits. Am J Vet Res 1978; 39:997-1010.
28. Van Vleet JF, Gerraus VJ, Weirich WE. Cardiac disease induced by chronic adriamycin administration in dogs and an evaluation of vitamin E and selenium as cardio-protectants. Am J Pathol 1980; 99:13-42.
29. Weiss JF, Hoover RL, Kumar KS. Selenium pretreatment enhances the radioprotective effect and reduces the lethal toxicity of WR-2721. Free Rad Res Commun 1987; 3:33-38.
30. Dobrić S, Milovanović SR, Jovanović D. Selenium increases the activity of alkaline phosphatase in rat liver: a possible mechanism of potentiation of radioprotector WR-2721 efficacy by selenium in rats. In: Benakis A, ed. Abstract book. 2nd Xenobiotic Metabolism and Toxicity Workshop of Balkan Countries. Ioannina, Greece, October 22-25, 1995: 34.
31. Ohnishi ST, Ohnishi T, Glick JH, Schein PS. In vitro study on the antioxidant activities of amifostine (WR-2721). Proc Am Assoc Cancer Res 1992; 33:419.
32. Dorr RT, Lagel KE. Anthracycline cardioprotection by amifostine (WR-2721) and its active metabolite (WR-1065) in vitro. Proc Am Soc Clin Oncol 1994; 13:435.
33. Green D, Wright A, Schein P, Clarke R. WR-2721 chemoprotection of doxorubicin toxicity in mice. Proc Am Assoc Cancer Res 1992; 33:490.
34. Green D, Bensely D, Schein P. Preclinical evaluation of WR-151327: An orally active chemotherapy protector. Cancer Res 1994; 54:738-741.
35. Bhanumathi P, Saleesh EB, Vasudevan DM. Creatinine phosphokinase and cardiotoxicity in adriamycin chemotherapy and its modification by WR-1065. Biochem Arch 1992; 8:335-338.
36. Bhanumathi P, Saleesh EB, Vasudevan DM. WR-1065 as a chemoprotector in adriamycin chemotherapy. Cancer Lett 1994; 81:171-175.
37. Polla BS, Donati Y, Kondo M, Tochon-Danguy HJ, Bonjour JP. Protection from cellular oxidative injury and calcium intrusion by N-(2-mercaptoethyl)-1,3-propanediamine, WR-1065. Biochem Pharmacol 1990; 40:1469-1475.
38. Ramakrishnan N, Catravs GN. N-(-2mercaptoethyl)-1,3-propanediamine (WR-1065) protects thymocytes from programmed cell death. J Immunol 1992; 148:1817-1821.
39. Dobrić S. General and cardioprotective action of radioprotector amifostine (WR- 2721) in irradiated rats. PhD thesis. Military Medical Academy, Belgrade, 1996 (in Serbian with English abstract).
40. Monti EL, Paracchini L, Piccinini F, Farelli L, Villani F. Effect of calcium mobilizers on doxorubicin accumulation in rat myocardial tissue. Pharmacol Res Commun 1988; 20:369-375.
41. Olson RD, Mushlin PS. Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB J 1990; 4:3076-3086.
42. Patchen ML, MacVittie TJ, Weiss JF. Combined modality radioprotection: the use of glucan and selenium with WR-2721. Int J Radiat Oncol Biol Phys 1990; 18:1069-1075.
43. Weiss JF, Kumar KS, Walden TL, Neta R, Landauer MR, Clark EN. Advances in radioprotection through the use of combined agent regimens. Int J Radiat Biol 1990; 57:709-722.